The EU-European Union has issued a marketing license to use the new coronavirus vaccine developed by the American pharmaceutical company Moderna.
This is the second time the EU has given permission for a new coronavirus vaccine.
On the 6th, EU drug regulator EMA = European Pharmaceutical Agency recommended issuing a "conditional marketing permit" for the Moderna vaccine under review, with a deadline of one year.
In response, the EU executive body, the European Commission, immediately proceeded with the procedure and issued a permit on the same day.
The European Commission is the second case to approve the vaccine for the new coronavirus, following the vaccine produced by Pfizer and others in the United States, and a total of 160 million doses will be given to EU member countries by autumn. It is supposed to be supplied.
Von der Leyen, chairman of the European Commission, said in a statement that he hoped to curb the spread of the infection as mutant viruses were found one after another, saying that "we will have enough vaccines to protect people."
However, the supply of vaccines such as Pfizer, which began to be inoculated at the end of last month, has been delayed, and the response of the EU and governments has been criticized.
In addition, it has been pointed out that the production capacity of the Moderna vaccine, which was approved this time, is limited in Europe, and it is unclear whether the vaccination will proceed as expected.